Fig. 6

R-loop score correlated with prognosis and therapeutic response. A Comparison of overall survival probability according to R-loop score in chemotherapy-treated patients from GSE42127 (NSCLC), GSE14814 (NSCLC), GSE25055 (BRCA), GSE25056 (BRCA), GSE32603 (BRCA), and GSE63885 (OV) cohorts (log-rank test). B Comparison of R-loop score between the progressive disease/nonresponse (PD/NR) groups and the response (RD) group from GSE25055 (BRCA), GSE25056 (BRCA), GSE20194 (BRCA), GSE41998 (BRCA), and GSE3964 (CRC) cohorts who underwent chemotherapy (Wilcoxon rank test). C The difference in the overall survival probability between patients with high R-loop scores and those with low R-loop scores from GSE61676 (NSCLC), GSE31428 (NSCLC), GSE41994 (BRCA), and GSE16391 (BRCA) cohorts who received targeted therapy. D The difference in the R-loop score between PD/NR and RD samples from GSE61676 (NSCLC), GSE68871 (MM), GSE16391 (BRCA), GSE109211 (LIHC), and GSE99898 (SKCM) cohorts who underwent targeted therapy (Wilcoxon rank test). E The difference in the overall survival probability between patients with high and low R-loop scores from GSE78220 (SKCM), GSE135222 (NSCLC), IMvigor210 (BLCA), and PMID32472114 (ccRCC) cohorts who received immunotherapy. F The difference in the R-loop score between PD/NR and RD samples from GSE135222 (NSCLC), IMvigor210 (BLCA), GSE78220 (SKCM), GSE91061 (SKCM), and PMID32472114 (ccRCC) cohorts who underwent immunotherapy (Wilcoxon rank test). G The overall predictive accuracy of the R-loop scoring model for immunotherapy in 16 dependent datasets across 6 tumor types. (*p < .05, **p < .01, ***p < .001)